

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Pivotal bioVenture Partners Fund I, L.P.</u>  (Last) (First) (Middle) 501 SECOND STREET, SUITE 200  (Street) SAN FRANCISCO CA 94107  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Inozyme Pharma, Inc. [ INZY ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/01/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/01/2023		P		119,048	A	\$4.8	2,923,110	I	See footnotes <sup>(1)</sup> (2)(3)
Common Stock	08/01/2023		P		714,285	A	\$4.8	1,571,741	I	See footnotes <sup>(2)</sup> (3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Pivotal bioVenture Partners Fund I, L.P.  
 (Last) (First) (Middle)  
 501 SECOND STREET, SUITE 200  
 (Street)  
 SAN FRANCISCO CA 94107  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Pivotal bioVenture Partners Fund I G.P., L.P.  
 (Last) (First) (Middle)  
 501 SECOND STREET, SUITE 200  
 (Street)  
 SAN FRANCISCO CA 94107  
 (City) (State) (Zip)

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Pivotal bioVenture Partners Fund I U.G.P. Ltd</a>		
(Last)	(First)	(Middle)
501 SECOND STREET, SUITE 200		
(Street)		
SAN FRANCISCO	CA	94107
(City)	(State)	(Zip)

**Explanation of Responses:**

- Held directly by Pivotal bioVenture Partners Fund I, L.P ("Pivotal I").
- The general partner of Pivotal I and Pivotal bioVenture Partners Fund II, L.P ("Pivotal II") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL").
- The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
- Held by Pivotal II.

[Pivotal bioVenture Partners Fund I, L.P. By: Robert Hopfner Managing Partner /s/ Robert Hopfner](#) [08/03/2023](#)

[Pivotal bioVenture Partners Fund G.P., L.P. By: Robert Hopfner Managing Partner /s/ Robert Hopfner](#) [08/03/2023](#)

[Pivotal bioVenture Partners Fund I U.G.P., Ltd. By: Robert Hopfner Managing Partner /s/ Robert Hopfner](#) [08/03/2023](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**